TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
5.48
+0.08 (1.48%)
Aug 19, 2026, 12:31 PM EDT - Market open
TriSalus Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 45.08 | 45.15 | 29.43 | 18.51 | 12.4 | 8.4 | |
Revenue Growth | 25.25% | 53.41% | 58.99% | 49.31% | 47.58% | 54.60% |
Cost of Revenue | 6.41 | 6.97 | 4.1 | 2.61 | 2.26 | 1.19 |
Gross Profit | 38.67 | 38.19 | 25.33 | 15.91 | 10.14 | 7.21 |
Selling, General & Admin | 54.55 | 50.17 | 43.81 | 36.25 | 25.22 | 17.02 |
Research & Development | 14.63 | 14.97 | 17.69 | 29.84 | 21.36 | 14.22 |
Operating Expenses | 69.18 | 65.13 | 61.49 | 66.08 | 46.58 | 31.24 |
Operating Income | -30.51 | -26.95 | -36.17 | -50.18 | -36.44 | -24.03 |
Interest Expense | -5.84 | -5.54 | -3.09 | -0.02 | -0 | -1.76 |
Interest & Investment Income | 0.97 | 0.56 | 0.4 | 0.43 | 0.18 | - |
Other Non Operating Income (Expenses) | 3.4 | -4.54 | -2.42 | -17.11 | -10.92 | -0.46 |
EBT Excluding Unusual Items | -31.98 | -36.48 | -41.27 | -66.87 | -47.18 | -26.25 |
Merger & Restructuring Charges | - | - | - | -4.3 | - | - |
Other Unusual Items | 3.78 | -2.74 | 11.23 | 11.81 | - | -2.59 |
Pretax Income | -28.2 | -39.22 | -30.04 | -59.35 | -47.18 | -28.84 |
Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Net Income | -28.21 | -39.23 | -30.05 | -59.36 | -47.19 | -28.85 |
Preferred Dividends & Other Adjustments | 29.04 | 30.46 | 3.19 | 4.24 | 2.83 | - |
Net Income to Common | -57.25 | -69.69 | -33.23 | -63.6 | -50.02 | -28.85 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 50 | 38 | 25 | 9 | 0 | 9 |
Shares Outstanding (Diluted) | 50 | 38 | 25 | 9 | 0 | 9 |
Shares Change | 73.15% | 49.61% | 169.61% | 2934.71% | -96.51% | 15.52% |
EPS (Basic) | -1.14 | -1.84 | -1.31 | -6.77 | -161.55 | -3.25 |
EPS (Diluted) | -1.15 | -1.84 | -1.31 | -6.77 | -161.55 | -3.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -23.28 | -18.93 | -41.19 | -51.17 | -32.97 | -23.79 |
Free Cash Flow Per Share | -0.47 | -0.50 | -1.63 | -5.45 | -106.48 | -2.68 |
Gross Margin | 85.79% | 84.57% | 86.06% | 85.93% | 81.79% | 85.80% |
Operating Margin | -67.68% | -59.68% | -122.88% | -271.06% | -293.91% | -286.06% |
Profit Margin | -127.00% | -154.35% | -112.92% | -343.59% | -403.42% | -343.35% |
Free Cash Flow Margin | -51.65% | -41.93% | -139.95% | -276.41% | -265.91% | -283.23% |
EBITDA | -29.95 | -26.32 | -35.42 | -49.49 | -36.04 | -23.57 |
EBITDA Margin | -66.44% | -58.29% | -120.35% | -267.36% | -290.70% | -280.54% |
D&A For EBITDA | 0.56 | 0.63 | 0.74 | 0.68 | 0.4 | 0.46 |
EBIT | -30.51 | -26.95 | -36.17 | -50.18 | -36.44 | -24.03 |
EBIT Margin | -67.68% | -59.68% | -122.88% | -271.06% | -293.91% | -286.06% |
Advertising Expenses | - | 1.4 | 0.5 | 1.3 | - | - |